meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - maintenance (M)
1
pancreatic ductal adenocarcinoma
PIK3CA-related overgrowth spectrum
prostate cancer (PC)
endocrine therapy
androgen deprivation therapy (ADT)
abiraterone plus ADT
abiraterone plus docetaxel plus ADT
apalutamide plus ADT
darolutamide plus doxetaxel plus ADT
docetaxel plus ADT
enzalutamide
enzalutamide plus ADT
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
anti-PD-(L)1
pembrolizumab based treatment
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs endocrine therapy
vs androgen deprivation therapy (ADT)
vs docetaxel plus ADT
vs enzalutamide
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
androgen deprivation therapy (ADT)
abiraterone plus ADT
Comparator:
vs androgen deprivation therapy (ADT);
Risk of bias:
low;
some concerns;
high;
NA;